drugset
Drugs / Prednisone
last change 2 days ago re-read 8 days ago

Prednisone

also known as prednison · prednisone acetate · PDN · PRED · Cortancyl · Lodotra · NSC-10023 · Apo-Prednisone Cordorol · +7 more

Other / unclassified targets TNF via inhibition

Developed for
lymphoma · diffuse large B-cell lymphoma · plasma cell myeloma · prostate cancer · Hodgkins lymphoma · leukemia · acute lymphoblastic leukemia · non-Hodgkin lymphoma
+303 more · peripheral T-cell lymphoma, not otherwise specified · rheumatoid arthritis · follicular lymphoma · HIV infectious disease · lymphoblastic lymphoma · prostate adenocarcinoma · asthma · metastatic prostate carcinoma · COVID-19 · granulomatosis with polyangiitis · heart failure · angioimmunoblastic T-cell lymphoma · B-cell acute lymphoblastic leukemia · castration-resistant prostate carcinoma · chronic obstructive pulmonary disease · large B-cell lymphoma · B-cell non-Hodgkin lymphoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic rhinosinusitis · classic Hodgkin lymphoma · Crohn disease · IgA glomerulonephritis · multiple sclerosis · post-transplant lymphoproliferative disease · temporal arteritis · adult acute lymphoblastic leukemia · high grade B-cell lymphoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · mantle cell lymphoma · marginal zone lymphoma · microscopic polyangiitis · myelodysplastic syndrome · sudden sensorineural hearing loss · acute graft versus host disease · adult T-cell leukemia/lymphoma · ALK-negative anaplastic large cell lymphoma · autoimmune disease · autoimmune thrombocytopenia · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · Burkitt lymphoma · cancer · chronic graft versus host disease · Duchenne muscular dystrophy · end stage renal failure · enteropathy-associated T-cell lymphoma · hepatosplenic T-cell lymphoma · idiopathic pulmonary fibrosis · myelofibrosis · nodular lymphocyte predominant Hodgkin lymphoma · optic neuritis · polymyalgia rheumatica · pregnancy loss, recurrent, 4 · primary mediastinal large B-cell lymphoma · prostate neoplasm · radiation-induced disorder · tuberculosis · type 2 diabetes mellitus · acquired polycythemia vera · ALK-positive anaplastic large cell lymphoma · anaplastic large cell lymphoma · anti-neutrophil cytoplasmic antibody-associated vasculitis · atherosclerosis · atopic eczema · B-cell adult acute lymphocytic leukemia · coronary restenosis · hepatocellular carcinoma · Hodgkin's lymphoma, lymphocytic depletion · Hodgkin's lymphoma, mixed cellularity · hormone-resistant prostate carcinoma · idiopathic membranous glomerulonephritis · idiopathic nephrotic syndrome · immunoglobulin A vasculitis · intrinsic cardiomyopathy · Langerhans cell histiocytosis · metastatic malignant neoplasm in the brain · minimal change disease · myocarditis · nasal cavity polyp · Nodal T-follicular helper cell lymphoma, follicular type · nodular sclerosis classical Hodgkin lymphoma · ocular myasthenia gravis · plasma cell neoplasm · pneumocystosis · pneumonia · poisoning · precursor B-cell acute lymphoblastic leukemia · prostate carcinoma · renal cell carcinoma · sciatica · sensorineural hearing loss disorder · subacute thyroiditis · symptomatic heart failure · systemic lupus erythematosus · T-cell acute lymphoblastic leukemia · T-cell non-Hodgkin lymphoma · T-cell/histiocyte rich large B cell lymphoma · Takayasu arteritis · thrombocytopenia · tinnitus · achalasia · acoustic neuroma · acquired hemophagocytic lymphohistiocytosis associated with malignant disease · acute asthma · acute kidney injury · acute myocarditis · acute transplant rejection · acute tubulointerstitial nephritis · aggressive B-cell non-Hodgkin lymphoma · alcoholic hepatitis · allergic bronchopulmonary aspergillosis · Alzheimer disease · arteritis · atrial fibrillation · atrioventricular block · autism · autoimmune pancreatitis · autoimmune thrombocytopenic purpura · autoimmune thyroid disease · B-cell childhood acute lymphoblastic leukemia · bacterial pneumonia · Becker muscular dystrophy · Bell's palsy · birdshot chorioretinopathy · brain injury · bronchiolitis obliterans syndrome · cardiac sarcoidosis · cat-scratch disease · cellulitis · central nervous system neoplasm · central nervous system non-hodgkin lymphoma · chemical colitis · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · cholesterol embolism · chondrocalcinosis · chronic congestive splenomegaly · chronic ethmoidal sinusitis · chronic hepatitis B virus infection · chronic kidney disease · chronic lymphoproliferative disorder of NK-cells · chronic maxillary sinusitis · chronic renal failure syndrome · chronic sphenoidal sinusitis · classic congenital adrenal hyperplasia · classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency · combined thymoma · complex regional pain syndrome · congenital adrenal hyperplasia · congestive heart failure · coronary artery disorder · cranial nerve neuropathy · cryptogenic organizing pneumonia · cystoid macular edema · diffuse large B-cell lymphoma germinal center B-cell type · diffuse large B-cell lymphoma of the central nervous system · disease related to solid organ transplantation · drug rash with eosinophilia and systemic symptoms · drug-induced liver injury · encephalomalacia · endocrine exophthalmos · eosinophilic granulomatosis with polyangiitis · erythema multiforme · esophageal disorder · estrogen-receptor positive breast cancer · facial paralysis · fetal and neonatal alloimmune thrombocytopenia · focal segmental glomerulosclerosis · follicular lymphoma, susceptibility to · gastric diffuse large B-cell lymphoma · generalized myasthenia gravis · giant cell myocarditis · granulomatous mastitis · habitual spontaneous abortion · halo nevus · hematopoietic and lymphoid cell neoplasm · hemophilia A · hepatitis · hepatitis C virus infection · HIV-associated nephropathy · hypereosinophilic syndrome · idiopathic cardiomyopathy · IgG4-related sclerosing cholangitis · immune reconstitution inflammatory syndrome · immunoglobulin G4-related sclerosing disease · infective arthritis · infertility disorder · inflammatory bowel disease 11 · inflammatory disease · intermediate uveitis · interstitial lung disease · ischemic disease · juvenile dermatomyositis · kidney cancer · kidney disorder · limb-girdle muscular dystrophy · long COVID-19 · long QT syndrome · lupus nephritis · lymphoid leukemia · lymphomatoid granulomatosis · lymphoplasmacytic lymphoma · lymphoproliferative syndrome · male infertility · MALT lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · mediastinal gray zone lymphoma · membranous glomerulonephritis · metastatic carcinoma in the bone · multicentric Castleman disease · Mycoplasma pneumoniae pneumonia · myelofibrosis with myeloid metaplasia · myeloproliferative neoplasm · neoplasm · nephrotic syndrome · neuromyelitis optica · nodal marginal zone B-cell lymphoma · non-amyloid fibrillary glomerulopathy · non-small cell squamous lung carcinoma · obstructive jaundice · pauci-immune glomerulonephritis with ANCA · pediatric lymphoma · peripheral nerve lesion · pleurisy · polyarteritis nodosa · post-infectious syndrome · precursor lymphoblastic lymphoma/leukemia · primary adrenal insufficiency · primary biliary cholangitis · primary myelofibrosis · prostate small cell carcinoma · pulmonary fibrosis · pulmonary sarcoidosis · refractory precursor T-lymphoblastic lymphoma/leukemia · relapsing-remitting multiple sclerosis · restless legs syndrome · rheumatic fever · rheumatic heart disease · Richter transformation · sickle cell disease · soft tissue sarcoma · splenic marginal zone lymphoma · subcutaneous panniculitis-like T-cell lymphoma · sudden hearing loss disorder · T-cell adult acute lymphocytic leukemia · T-cell large granular lymphocyte leukemia · T-lymphoblastic lymphoma · testicular lymphoma · thrombocytosis disease · transplant rejection · ulcerative colitis · undifferentiated connective tissue syndrome · urticaria · uveitis · ventricular tachycardia · vestibular disorder · viral pneumonia · vitiligo · Waldenstrom macroglobulinemia · allergic rhinitis · aortitis · autoimmune hemolytic anemia · autoimmune hepatitis · autoimmune pancreatitis type 1 · B-cell neoplasm · bullous pemphigoid · capillary infantile hemangioma · croup · cystic fibrosis · demyelinating polyneuropathy · disease of orbital part of eye adnexa · disease of the tendon · drug-induced hepatitis · dry eye syndrome · extranodal nasal NK/T cell lymphoma · glomerular disorder · gout · hemangioma · kaposiform hemangioendothelioma · kidney failure · large-cell immunoblastic lymphoma · lichen planus, oral · liver disorder · lower respiratory tract disorder · myasthenia gravis · neuromyelitis optica spectrum disorder with anti-AQP4 antibodies · olfactory nerve disorder · orthostatic hypotension · osteoarthritis · osteoarthritis, hip · osteoarthritis, knee · panuveitis · pediatric arterial ischemic stroke · pericarditis · peripheral vertigo · post-traumatic stress disorder · posterior uveitis · sinusitis · status asthmaticus · thrombotic thrombocytopenic purpura · thyroid gland disorder · type IV hypersensitivity disease · vasculitis · vestibular neuronitis
Investigated by
National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Alliance for Clinical Trials in Oncology · Celgene Corporation · Children's Oncology Group · PETHEMA Foundation
+546 more · SWOG Cancer Research Network · Assistance Publique - Hôpitaux de Paris · Memorial Sloan Kettering Cancer Center · St. Jude Children's Research Hospital · European Organisation for Research and Treatment of Cancer - EORTC · The First Affiliated Hospital with Nanjing Medical University · Eastern Cooperative Oncology Group · Fondazione Italiana Linfomi - ETS · Hoffmann-La Roche · Janssen Research & Development, LLC · Mayo Clinic · Merck Sharp & Dohme LLC · Peking Union Medical College Hospital · Ruijin Hospital · University of Washington · Amgen · Hebei Medical University · Lymphoma Study Association · Massachusetts General Hospital · National Institute of Allergy and Infectious Diseases (NIAID) · Tongji Hospital · Dana-Farber Cancer Institute · Fondazione EMN Italy Onlus · Genentech, Inc. · Institute of Hematology & Blood Diseases Hospital, China · National Heart, Lung, and Blood Institute (NHLBI) · Novartis Pharmaceuticals · Stanford University · Takeda · Tianjin Medical University Cancer Institute and Hospital · University of Cologne · Xiangya Hospital of Central South University · AbbVie · Bayer · Bristol-Myers Squibb · Children's Cancer Group, China · Nanjing Children's Hospital · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Nordic Lymphoma Group · Northwestern University · Ortho Biotech, Inc. · Peking University People's Hospital · Qilu Hospital of Shandong University · Sanofi · Shanghai Children's Medical Center · Sun Yat-sen University · University of Miami · University of Rochester · West China Second University Hospital · Astellas Pharma Inc · Children's Hospital of Soochow University · Eli Lilly and Company · Eye & ENT Hospital of Fudan University · French Innovative Leukemia Organisation · Fudan University · Genmab · Henan Cancer Hospital · Hospices Civils de Lyon · McMaster University · Millennium Pharmaceuticals, Inc. · NCIC Clinical Trials Group · National Institute of Neurological Disorders and Stroke (NINDS) · Peking University · Seagen Inc. · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · UNICANCER · University Health Network, Toronto · University of British Columbia · University of Nebraska · University of Pittsburgh · University of Wisconsin, Madison · Washington University School of Medicine · AIDS Malignancy Consortium · all 552 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) METICORTEN — 1955-02-21 fda.gov ↗

Trials 652 · started per year

today
US approved 1955
1
1
2
3
2
2
5
7
5
5
6
9
14
16
14
22
15
19
27
28
24
25
24
22
22
20
21
16
18
31
15
22
19
23
21
22
28
25
25
23
1
195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 09 trials
Phase 0 NCT06934915 Nov 2026 → Jul 2028 expected autism Christopher John McDougle, M.D. Not yet recruiting No outcome recorded
Phase 0 NCT07039019 May 2025 → Jun 2027 expected pleurisy Icahn School of Medicine at Mount Sinai Recruiting No outcome recorded
Phase 0 NCT06588348 Jul 2022 → Nov 2026 expected esophageal disorder Baylor Research Institute Active not recruiting No outcome recorded
Phase 0 NCT04988256 Sep 2021 → Apr 2026 overdue drug rash with eosinophilia and systemic symptoms University of Southern California Enrolling by invitation No outcome recorded
Phase 0 NCT04357392 May 2020 → May 2022 type 2 diabetes mellitus chenfengling Unknown No outcome recorded
Phase 0 NCT03719105 Mar 2019 → Dec 2027 expected aggressive NK-cell leukemia New York Medical College Recruiting No outcome recorded
Phase 0 NCT03367663 Jan → Jul 2018 atherosclerosis, diabetes mellitus, hyperlipidemia Prof. Tony hayek MD Completed No outcome recorded
Phase 0 NCT03661684 Jun 2016 → Apr 2017 hyperglycemia, type 2 diabetes mellitus Cook County Health Completed No outcome recorded
Phase 0 NCT00486421 Jan 2007 → May 2008 — Mayo Clinic Completed No outcome recorded
Phase 128 trials · 1 met primary
Phase 1 NCT07832266 Mar 2027 → Sep 2030 expected oropharynx cancer, peripheral nerve lesion M.D. Anderson Cancer Center Not yet recruiting No outcome recorded
Phase 1 NCT07278856 Dec 2025 → Mar 2027 expected Nodal T-follicular helper cell lymphoma, follicular type, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT07207954 Oct 2025 → Jul 2027 expected rheumatoid arthritis Lifordi Immunotherapeutics, Inc. Recruiting No outcome recorded
Phase 1 NCT06119529 Nov 2023 → Apr 2024 atopic eczema Eli Lilly and Company Terminated No outcome recorded
Phase 1 NCT05818683 Apr 2023 → Aug 2027 expected prostate carcinoma Janssen Research & Development, LLC Recruiting No outcome recorded
Phase 1 NCT05211336 Apr 2022 → Jun 2024 overdue diffuse large B-cell lymphoma of the central nervous system National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT05176483 Dec 2021 → Jan 2027 expected castration-resistant prostate carcinoma, clear cell renal carcinoma, colorectal cancer, head and neck squamous cell carcinoma +3 Exelixis Recruiting No outcome recorded
Phase 1 NCT04666129 Feb 2021 → May 2024 castration-resistant prostate carcinoma, metastatic prostate carcinoma Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 1 NCT04083898 Apr 2020 → Mar 2023 plasma cell myeloma Washington University School of Medicine Terminated No outcome recorded
Phase 1 NCT03750383 Nov 2018 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 1/230 trials · 1 missed
Phase 1/2 NCT07496229 Apr 2026 → Sep 2029 expected T-cell non-Hodgkin lymphoma Dizal Pharmaceuticals Recruiting No outcome recorded
Phase 1/2 NCT06631300 Oct 2024 → Jun 2025 overdue restless legs syndrome Scripps Health Not yet recruiting No outcome recorded
Phase 1/2 NCT06568094 Sep 2024 → Dec 2026 expected prostate cancer Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06457919 Jun 2024 → Jun 2027 expected prostate cancer Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT06040320 Oct 2023 → May 2027 expected post-transplant lymphoproliferative disease Washington University School of Medicine Active not recruiting No outcome recorded
Phase 1/2 NCT05123040 Jun 2023 → Feb 2026 acute graft versus host disease Masonic Cancer Center, University of Minnesota Terminated No outcome recorded Stop: Business
Phase 1/2 NCT05498636 Oct 2022 → Jul 2025 diffuse large B-cell lymphoma The Affiliated Hospital of Qingdao University Unknown No outcome recorded
Phase 1/2 NCT05197842 Feb 2022 → Mar 2025 anti-neutrophil cytoplasmic antibody-associated vasculitis Staidson (Beijing) Biopharmaceuticals Co., Ltd Completed No outcome recorded
Phase 1/2 NCT04623541 Nov 2020 → Dec 2027 expected Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma Genmab Active not recruiting Missed primary
Phase 1/2 NCT04300556 Aug 2020 → Aug 2030 expected cancer Eisai Inc. Recruiting No outcome recorded
Phase 2278 trials · 10 met primary · 7 missed
Phase 2 NCT07443436 Nov 2026 → Nov 2027 expected interstitial lung disease Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT07663422 Jul 2026 → Mar 2028 expected hepatitis Fox Chase Cancer Center Recruiting No outcome recorded
Phase 2 NCT07643103 Jun 2026 → May 2028 expected precursor B-cell acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT07608978 Jun 2026 → Dec 2028 expected diffuse large B-cell lymphoma The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 2 NCT06738368 May 2026 → Jan 2028 B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia University of Washington Suspended No outcome recorded
Phase 2 NCT07552324 May 2026 → May 2027 expected T-cell/histiocyte rich large B cell lymphoma Ruijin Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07237269 Apr 2026 → Apr 2033 expected prostate cancer University of Nebraska Recruiting No outcome recorded
Phase 2 NCT07440238 Mar → Sep 2026 overdue infective arthritis Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT07224100 Mar 2026 → Jul 2028 expected B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), lymphoblastic lymphoma University of Washington Recruiting No outcome recorded
Phase 2 NCT07535762 Mar 2026 → Dec 2027 expected ALK-negative anaplastic large cell lymphoma, Nodal T-follicular helper cell lymphoma, follicular type, peripheral T-cell lymphoma, not otherwise specified Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Show all 278 trials opens the full record — a long page
Phase 2/331 trials · 2 met primary · 3 missed
Phase 2/3 NCT07168980 Jul 2025 → Jun 2030 expected B-cell non-Hodgkin lymphoma Children's Cancer Group, China Recruiting No outcome recorded
Phase 2/3 NCT07059156 Jun 2025 → Jun 2027 expected adult acute lymphoblastic leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2/3 NCT06591468 Oct 2024 → Dec 2027 expected primary biliary cholangitis Han Ying Enrolling by invitation No outcome recorded
Phase 2/3 NCT06563245 Sep 2024 → Nov 2029 expected classic Hodgkin lymphoma Children's Cancer Group, China Recruiting No outcome recorded
Phase 2/3 NCT06103227 Nov 2023 → Nov 2024 — University of Mostar Completed No outcome recorded
Phase 2/3 NCT05809011 Apr 2023 → Nov 2025 heart failure Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Unknown No outcome recorded
Phase 2/3 NCT05095961 Mar 2023 → Mar 2024 chronic ethmoidal sinusitis, chronic maxillary sinusitis, chronic sphenoidal sinusitis Loma Linda University Withdrawn No outcome recorded
Phase 2/3 NCT05668676 Feb 2023 heart failure Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 2/3 NCT04558268 Dec 2020 → Jul 2021 pregnancy loss, recurrent, 4 Soroka University Medical Center Unknown No outcome recorded
Phase 2/3 NCT04492358 Oct 2020 → May 2021 COVID-19 Maria Joyera Rodríguez Terminated Missed primary Stop: Enrollment
Phase 3119 trials · 14 met primary · 17 missed
Phase 3 NCT07830108 Dec 2026 → Dec 2034 expected rheumatic fever, rheumatic heart disease Starship Child Health, Te Toka Tumai Auckland Not yet recruiting No outcome recorded
Phase 3 NCT06474273 Mar 2026 → Jun 2030 expected acute transplant rejection University of Sydney Recruiting No outcome recorded
Phase 3 NCT07215585 Nov 2025 → Jun 2030 expected large B-cell lymphoma AstraZeneca Recruiting No outcome recorded
Phase 3 NCT06983821 Nov 2025 → Feb 2028 expected granulomatosis with polyangiitis, microscopic polyangiitis Ottawa Hospital Research Institute Recruiting No outcome recorded
Phase 3 NCT07067801 Nov 2025 → Dec 2028 expected sudden sensorineural hearing loss Centre Hospitalier Universitaire de Besancon Not yet recruiting No outcome recorded
Phase 3 NCT07116811 Sep 2025 → Sep 2026 overdue acoustic neuroma, facial paralysis Beijing Tiantan Hospital Not yet recruiting No outcome recorded
Phase 3 NCT06342544 Apr 2025 → Jun 2028 expected ocular myasthenia gravis Fondation Ophtalmologique Adolphe de Rothschild Recruiting No outcome recorded
Phase 3 NCT06522100 Feb 2025 → Aug 2028 expected acute myocarditis Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 3 NCT06635720 Nov 2024 → Feb 2026 overdue idiopathic nephrotic syndrome, minimal change disease The Hospital for Sick Children Active not recruiting No outcome recorded
Phase 3 NCT06520163 Aug 2024 → Aug 2026 overdue non-Hodgkin lymphoma The Affiliated People's Hospital of Ningbo University Recruiting No outcome recorded
Show all 119 trials opens the full record — a long page
Phase 497 trials · 2 met primary · 5 missed
Phase 4 NCT07683975 Sep 2026 → Jan 2029 expected acute kidney injury, acute tubulointerstitial nephritis Massachusetts General Hospital Recruiting No outcome recorded
Phase 4 NCT07451665 Apr 2026 → Mar 2029 expected Takayasu arteritis Chinese SLE Treatment And Research Group Not yet recruiting No outcome recorded
Phase 4 NCT07245732 Apr 2026 → Mar 2029 expected rheumatoid arthritis Sunnybrook Health Sciences Centre Recruiting No outcome recorded
Phase 4 NCT07221838 Mar 2026 → Aug 2027 expected generalized myasthenia gravis Alexion Pharmaceuticals, Inc. Recruiting No outcome recorded
Phase 4 NCT07223580 Jan 2026 → Jan 2027 expected urolithiasis Mayo Clinic Recruiting No outcome recorded
Phase 4 NCT06970080 Jun 2025 → Jun 2028 expected asthma McMaster University Recruiting No outcome recorded
Phase 4 NCT04568837 Mar 2025 → Oct 2026 expected — Oregon Health and Science University Not yet recruiting No outcome recorded
Phase 4 NCT06833814 Feb → Dec 2025 overdue acute asthma Andréanne Côté Not yet recruiting No outcome recorded
Phase 4 NCT06635863 Nov 2024 → Oct 2026 expected idiopathic cardiomyopathy, intrinsic cardiomyopathy, ventricular tachycardia Roderick Tung Enrolling by invitation No outcome recorded
Phase 4 NCT06510114 Jul 2024 → Jun 2026 overdue endocrine exophthalmos Third Affiliated Hospital, Sun Yat-Sen University Not yet recruiting No outcome recorded
Phase not applicable59 trials · 2 met primary · 3 missed
— NCT07443592 Mar 2026 → Mar 2031 expected acute lymphoblastic leukemia PETHEMA Foundation Not yet recruiting No outcome recorded
— NCT07307534 Jan 2026 → Oct 2027 expected halo nevus, vitiligo Xijing Hospital Not yet recruiting No outcome recorded
— NCT06981845 Jun 2025 → Jun 2028 expected coronary restenosis China National Center for Cardiovascular Diseases Not yet recruiting No outcome recorded
— NCT06597682 Mar 2025 → Jul 2027 expected long COVID-19 Huashan Hospital Not yet recruiting No outcome recorded
— NCT06453447 Oct 2024 → May 2027 expected complex regional pain syndrome University of British Columbia Recruiting No outcome recorded
— NCT06124703 Nov 2023 → Feb 2024 sensorineural hearing loss disorder, tinnitus Eye & ENT Hospital of Fudan University Unknown No outcome recorded
— NCT06245707 Oct 2023 → Sep 2025 cognitive impairment with or without cerebellar ataxia, idiopathic membranous glomerulonephritis Beijing Friendship Hospital Unknown No outcome recorded
— NCT05916586 Aug 2023 → Apr 2024 heart failure Heart Initiative Completed Met primary
— NCT05855395 May 2023 → May 2024 COVID-19 Huashan Hospital Unknown Missed primary
— NCT05896813 Mar 2023 → Jan 2025 peripheral T-cell lymphoma, not otherwise specified The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
Phase not stated1 trial
— NCT00799539 — plasma cell myeloma Janssen-Ortho Inc., Canada No longer available No outcome recorded
Comparator or background therapy1,334 trials
Phase 0 NCT07806136 Background Aug 2026 → Feb 2029 expected — Virginia Commonwealth University Not yet recruiting No outcome recorded
Phase 0 NCT04469842 Background Dec 2023 → Jun 2027 expected transplant-related bronchiolitis obliterans Vanderbilt University Medical Center Recruiting No outcome recorded
Phase 0 NCT04139304 Background May 2021 → Jul 2029 expected plasmablastic lymphoma AIDS Malignancy Consortium Recruiting No outcome recorded
Phase 0 NCT04146207 Background Apr 2020 → Sep 2024 chronic graft versus host disease Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Completed No outcome recorded
Phase 0 NCT03457025 Background Aug 2019 → Jun 2020 Bell's palsy NYU Langone Health Withdrawn No outcome recorded Stop: Enrollment
Show all 1,334 trials opens the full record — a long page

Press releases naming this drug 32 releases

DateIssuerRelease
2023-10-22 Janssen Research & Development, LLC Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone jnj.com ↗
2023-10-22 Janssen Research & Development, LLC Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone jnj.com ↗
2023-06-01 Merck Sharp & Dohme LLC FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) merck.com ↗
2023-04-28 Merck Sharp & Dohme LLC Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer merck.com ↗
2023-03-02 Merck Sharp & Dohme LLC Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer merck.com ↗
2023-03-01 Janssen Research & Development, LLC Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations jnj.com ↗
2023-02-28 Janssen Research & Development, LLC Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations jnj.com ↗
2023-02-27 Janssen Research & Development, LLC Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer jnj.com ↗
2023-02-24 Janssen Research & Development, LLC Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer jnj.com ↗
2023-02-16 Janssen Research & Development, LLC Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer jnj.com ↗
2023-02-16 Janssen Research & Development, LLC Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration - Resistant Prostate Cancer jnj.com ↗
2022-12-21 Merck Sharp & Dohme LLC LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer merck.com ↗

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 1,990 sources stand behind the page.

FieldValueCited text
Known as Prednisone “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗
1954

“Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8,...” NCT06211452 ↗

“A Phase 3 Open Label Multicenter, Randomized Study to Compare the Efficacy and Safety of the Zevalin (Ibritumomab Tiuxetan) Therapeutic Regimen Following Cyclophosphamide,...” NCT00384111 ↗

“The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1...” NCT04842318 ↗

“The purpose of this study is to assess whether a 5-day treatment with orally administered prednisone provides patient-relevant benefits by improving the cough-related QoL of...” NCT04232449 ↗

“Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally...” NCT00149890 ↗

“Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before...” PMID 39874233 ↗ Jan 2025

“The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and...” NCT01393756 ↗

“bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4...” NCT01118026 ↗

“1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after...” NCT04966884 ↗

“After enrollment and randomization, patients assigned to corticosteroid therapy will receive it as a single-bolus intravenous injection of dexamethasone 20 mg (day 1), followed...” NCT05809011 ↗

Show 1,944 more sources
Known as Apo-Prednisone Cordorol “Apo-Prednisone Cordorol, Detasone - Prednisone” NCT01903486 ↗
Known as Cortancyl “patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl).” NCT00686335 ↗
4

“Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week” NCT01407484 ↗

“Patients assigned to this group will receive Prednisone : Cortancyl 20mg.” NCT03128905 ↗

“C : prednisone (CORTANCYL)” NCT02552251 ↗

“Prednisone (Cortancyl®)” NCT02627417 ↗
Known as Decortin ClinicalTrials.gov intervention name — accepted as the source's own label NCT01092533 ↗
Known as Deltacortene “Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1” NCT03161054 ↗
Known as deltacortene (prednisone) “deltacortene (prednisone)” NCT00480272 ↗
Known as Detasone “Apo-Prednisone Cordorol, Detasone - Prednisone” NCT01903486 ↗
Known as ESCALATED BEACOPP ClinicalTrials.gov intervention name — accepted as the source's own label NCT00795613 ↗
Known as Lodotra “The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard...” NCT00650078 ↗
3

“A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma” NCT00686335 ↗

“Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR)” NCT01821040 ↗

“Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)” NCT02072200 ↗
Known as NSC-10023 “Prednisone, PRED, NSC-10023” NCT00002499 ↗
3

“Prednisone, PRED, NSC-10023” NCT00002462 ↗

“PRED Prednisone, NSC-10023” NCT00002565 ↗

“PRED Prednisone, NSC-10023” NCT00002599 ↗
Known as PDN “This study compared the efficacy and safety of high-dose dexamethasone (HD-DXM) and conventional prednisone (PDN) on the largest cohort to date as first-line strategies for...” PMID 26480931 ↗ Oct 2015
11

“Participants will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT07443592 ↗

“Patients will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT04179929 ↗

“Prednisone(PDN) is the standard corticosteroid therapy in ITP practical guideline usually given at 1 mg/kg per day for 4 weeks and then tapered.” NCT02914054 ↗

“Prednisone (PDN) on days 1-7 and one dose of methotrexate (MTX) intrathecal (IT) on day 1” NCT01117441 ↗

“Prednisone ( PDN ): 60 mg/m2 night , i.v. or p.o , 1-14 days” NCT02036489 ↗

“MPDN= methylprednisolone pulse PDN= prednisone or equivalent” NCT00323960 ↗

“Prednisone (PDN): 60 mg/m2/day, i.v. or p.o., days 1 to 14” NCT00526305 ↗

“Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.” NCT02776605 ↗

“Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28” NCT00853008 ↗

“35 patients received prednisone (PDN) 40 mg/d” PMID 25945012 ↗ Apr 2015

Show 1 more source
Known as PRED “We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers.” PMID 38252910 ↗ Jan 2024
11

“Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred” NCT04976465 ↗

“Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) ]± Rituximab (R)” NCT06520163 ↗

“Patients receive prednisone (PRED) on days 8-28.” NCT00613457 ↗

“oral prednisone (PRED) once daily on days 1-28” NCT00002514 ↗

“methylprednisolone (MP) or prednisone (pred)” NCT00657059 ↗

“Prednisone, PRED, NSC-10023” NCT00002499 ↗

“Prednisone, PRED, NSC-10023” NCT00002462 ↗

“PRED Prednisone, NSC-10023” NCT00002565 ↗

“PRED Prednisone, NSC-10023” NCT00002757 ↗

“PRED Prednisone, NSC-10023” NCT00002599 ↗

Show 1 more source
Known as prednison “standard CHOP chemotherapy (cyclophosphamide, 750mg per square meter of body-surface area,d1, vincristine, 1.4mg per square meter of body-surface area, maximal dose is 2mg d1,...” NCT02487316 ↗
17

“cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid...” NCT05498259 ↗

“Week 2-4 Prednison - 0,5-0,3 mg/kg/D Week 4-12 Prednison -0,3-0,2 mg/kg/D Month 4-6 Prednison 0,2 - 0,1 mg/kg/D Month 7 - Steroid withdrawal” NCT00195988 ↗

“Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician” NCT01958190 ↗

“Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days” NCT04424862 ↗

“The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.” NCT05933967 ↗

“Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP)” NCT01352338 ↗

“The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.” NCT05234684 ↗

“etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times” NCT01502982 ↗

“Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w” NCT00991211 ↗

“Prednison：100mg/d，po，D1-5；” NCT02526823 ↗

Show 7 more sources
Known as Prednisone (P) “Prednisone (P)” NCT01858922 ↗
Known as prednisone acetate “Prednisone acetate tablets administered orally once daily, starting at 30 mg/day and tapered according to the protocol-specified schedule.” NCT07814664 ↗
15

“Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage” NCT05969522 ↗

“oral prednisone (prednisone acetate, 0.3 mg/kg/day) is added to the above stable-stage regimen.” NCT07307534 ↗

“switch to oral prednisone acetate tablets after 5 days (calculated at 0.75 mg/kg/day)” NCT07546097 ↗

“prednisone acetate tablets (prednisone) 5 mg, once a day” NCT05376722 ↗

“Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po” NCT04026269 ↗

NCT06689163 ↗

NCT05405439 ↗

NCT06568094 ↗

NCT03591471 ↗

NCT06136650 ↗

Show 5 more sources
Known as prednisone tablets ClinicalTrials.gov intervention name — accepted as the source's own label NCT02871869 ↗
Action Inhibit “According to it, we designed to inhibit the immune response at multi-targets with Prednisone Combined With MMF and FK506.” NCT00956059 ↗
Modality Other / unclassified “corticosteroid treatment” NCT00000146 ↗
Route Oral “Oral prednisone” NCT00000146 ↗
Target TNF “TNF inhibition (prednisone)” NCT04497584 ↗